Abacavir/Lamivudine/Lopinavir/Ritonavir

阿巴卡韦/拉米夫定/洛匹那韦/利托那韦

Report date: 2022/12/07 17:07:38

Base Information

Drug NameAbacavir/Lamivudine/Lopinavir/Ritonavir
Drug Alias NameLopinavir + Ritonavir + Abacavir + Lamivudine (capsulated granules, HIV infection), Cipla/Drugs for Neglected Diseases Initiative洛匹那韦/阿巴卡韦/拉米夫定/利托那韦洛匹那韦+阿巴卡韦+拉米夫定+利托那韦Lamivudine/Abacavir/Lopinavir/Ritonavir阿巴卡韦+拉米夫定+洛匹那韦+利托那韦 +[12] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHuman immunodeficiency virus type 1 protease inhibitorsReverse transcriptase inhibitors
TargetsHuman immunodeficiency virus type 1 proteaseReverse transcriptase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes LamivudineRitonavirAbacavir Sulfate
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCipla IncDrugs For Neglected Diseases Initiative
China Registration ClassN/A

Develop Information

Active CompaniesCipla IncDrugs For Neglected Diseases Initiative
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A